Docefrez, Docetaxel, Taxotere, Docetaxel Winthrop, Docetaxel Zentiva (docetaxel) is a small molecule pharmaceutical. Docetaxel was first approved as Docefrez on 1995-11-27. It is used to treat breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, and ovarian neoplasms amongst others in the USA. It has been approved in Europe to treat adenocarcinoma, breast neoplasms, head and neck neoplasms, non-small-cell lung carcinoma, and prostatic neoplasms amongst others. The pharmaceutical is active against tubulin beta chain. Docetaxel's patents are valid until 2033-09-30 (FDA).
|Trade Name||Docetaxel Winthrop, Docetaxel Zentiva, Taxotere|
|Indication||adenocarcinoma, breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, ovarian neoplasms, pancreatic neoplasms, prostatic neoplasms, soft tissue neoplasms, stomach neoplasms|
|Drug Class||Antineoplastics, taxane derivatives|